The dated record behind your claim, and a probability registered before your review
Each program is scoped to a decision with a date: a P&T meeting, an HTA submission, a label negotiation, or a deal closing. You can start with one claim at a fixed price and extend the same record to the rest of your portfolio.
What a program is scoped around
- The claim, drug, or therapeutic class your team needs to review.
- The decision it feeds: an evidence strategy, a market access plan, a claim review.
- The date that decision is due, and the period the reconstruction has to cover.
Claim Intelligence
A dated, sourced record of how the claims about your drugs, competitor indications, or a whole therapeutic class are worded and supported across FDA and EMA labels, NCCN and other guidelines, coverage policies, and trial literature, and where those sources disagree.
Start with one claim before your deadline
Name one contested claim, coverage restriction, or guideline criterion, who decides it, and the review it goes into. For that claim, that decision-maker, and that date, a single-claim evaluation is a fixed $15,000 and delivers within ten business days: the dated evidence baseline, a comparison showing which qualifiers changed, a reading of where the evidence has stalled, and your question registered as a forecast before your deadline.
You pay for the question and the work behind it. The probability itself is public, so your team can share it by link.
Then keep it current across the portfolio
The same record can cover every asset and decision your portfolio is waiting on, refreshed on a cadence you set, with a registered probability for each decision that has a date.
- Claim history. When the claim first appeared, each change to its wording and evidence, whether it was contested, and how long it held. Every step carries the revision date and its source document.
- Cohort analysis. Which claims are shared, contested, or unique to one drug in the class.
- Claims you name. A dated record of every public change to each, including the finding that a claim has not moved.
Rebuilt from dated public revisions. Adverse-event, REMS, boxed-warning, and recall-safety evidence stays outside the record by design (evidence boundary).
A source-linked history for the next review
An evaluation brings label versions, guideline editions, and coverage policy PDFs into one dated, source-linked history. Your team can use that history again at the next review.
See a real one: an evidence ledger from the public record, with a source and a digest on every row
Every evaluation arrives as four documents
- Executive Briefing Memo
- Three to five pages for your CMO, head of market access, or deal team: the contested claims, how each authority's published wording has changed, and the decision dates ahead.
- Claim Vulnerability Matrix
- A redline of your asset's claims across FDA label text, NCCN guideline versions, and major payer coverage policies, marking where the wording diverges.
- Evidence Gap Roadmap
- The endpoints and real-world evidence that the authority's published record asks for and your dossier does not yet answer, set against your submission calendar.
- Verifiable Audit Ledger
- Every source revision, evidence cutoff, and forecast probability, dated, in one ledger your compliance and regulatory teams can hand to a reviewer.
Inside every evaluation, or on its own
A registered forecast on the change you are waiting for
A probability that a defined action is taken by your date: a guideline body changing a recommendation, a regulator changing a label, a payer changing coverage.
29 forecasts registered in public, 0 resolved; the next deadline is . Read them all, or read how a forecast is scored.
Three questions buyers ask first
- How is the number formed?
- We assess four inputs at the evidence cutoff: the public evidence behind the claim; the status of the submission or review and the authority's schedule; comparable past decisions; and evidence or procedural constraints against the proposed action. The reasoning is published beside the probability.
- What happens when a forecast is wrong?
- It stays published, beside the reasoning that produced it, and counts in its class's score.
- How does a program run?
- A fixed-scope statement of work names the claims, the period covered, and each deliverable with its date. The evidence record arrives as a dated, sourced document with a digest on every archived copy. One named contact, and a reply within one business day.
How a program starts
Four steps. The signature is the last one.
- First conversation
Send the drug, class, or area and the decision it feeds. Public sources and high-level context are enough, and a mutual NDA can come first if you want one.
- Confirm the scope
Within one business day, at no charge, we confirm whether the public sources support an evaluation. If they do not, we explain why.
- Fixed-scope statement of work
It fixes the drugs, the look-back period, the claims covered, the deliverables and their dates, and the price.
- Contracting and delivery
Any confidentiality, data-processing, retention, and delivery terms are settled in writing before work starts.
On pricing. Beyond one claim, four things set the figure: how many drugs or claims, how many decision-makers, how far back the record goes, and whether it is kept current or delivered once. The figure is in the statement of work.
Validation status, by type of forecast
Forecasts are offered on judgment. As of the 2026-10-06 registry snapshot, 29 are registered in public and 0 have resolved; a class gets a calibration figure once 15 in it have resolved.